SciELO - Scientific Electronic Library Online

 
vol.21 issue3Effects of glucagon-like peptide-1 receptor antagonist in the treatment of patients with obesity and Type 2 diabetes mellitusCharacterization of older adults with type 2 diabetes, according to clinical and epidemiological variables. Punta Brava, 2020 author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Article

Indicators

  • Have no cited articlesCited by SciELO

Related links

  • Have no similar articlesSimilars in SciELO

Share


Revista Habanera de Ciencias Médicas

On-line version ISSN 1729-519X

Abstract

LLIBRE-RODRIGUEZ, Juan de Jesús; GUTIERREZ HERRERA, Raúl  and  GUERRA HERNANDEZ, Milagros A.. Alzheimer's disease: update in prevention, diagnosis and treatment. Rev haban cienc méd [online]. 2022, vol.21, n.3  Epub June 10, 2022. ISSN 1729-519X.

Introduction:

Worldwide, nearly 55 million people are living with dementia. It is estimated that this number will reach nearly 82 million in 2030 and over 152 million in 2050, unless the risk factors are identified and interventions are implemented to prevent, delay the onset, and slow or stop its progression.

Objective:

To provide an update on recent changes in the epidemiology, diagnosis and treatment of Alzheimer's disease.

Material and Methods:

Bibliographic review of the literature on this subject published between January 1, 2012 and December 30, 2021 in PubMed/MEDLINE, EMBASE Lilacs, SciELO and Cochrane CENTRAL databases, using the terms " Alzheimer”, OR “dementia”, OR “cognitive impairment”.

Results:

The governments must prepare for a tsunami of demands for health services as a result of the world population aging and improve the diagnoses, including biomarkers and emerging pharmacological treatments. The timely detection of cognitive impairment, and the causal diagnosis and proper management of the nosological entity is crucial.

Conclusions:

The health systems should introduce annual neurocognitive assessments on a global level for people over 55 years of age, facilitated by the development of biomarker science, with the opportunity to promote risk reduction strategies. The existence of potentially modifiable risk factors means that dementia can be prevented through the implementation of a public health strategy with key interventions that delay or slow down the onset of cognitive impairment and dementia.

Keywords : Dementia; Alzheimer's disease; cognitive impairment; prevention; biomarkers.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )